Evidence map›Paper›PMID 36295538›Full record

ReviewMedicina (Kaunas, Lithuania)2022

Molecular Pathways Related to Sulforaphane as Adjuvant Treatment: A Nanomedicine Perspective in Breast Cancer.

María Zenaida Saavedra-Leos, Euclides Jordan-Alejandre, Jonathan Puente-Rivera, Macrina Beatriz Silva-Cázares

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

María Zenaida Saavedra-LeosAcademic Coordination of the Altiplano Region, University Autonomous of San Luis Potosi, San Luis Potosi 78700, Mexico.ORCID 0000-0001-6721-7114
Euclides Jordan-AlejandreGenomics Sciences Prograde, Autonomous University of Mexico City, Mexico City 03100, Mexico.ORCID 0000-0003-0374-4454
Jonathan Puente-RiveraDivision of Health, Biological and Environmental Sciences, Open and Distance University of Mexico, Mexico City 03330, Mexico.ORCID 0000-0001-6941-6248
Macrina Beatriz Silva-CázaresAcademic Coordination of the Altiplano Region, University Autonomous of San Luis Potosi, San Luis Potosi 78700, Mexico.ORCID 0000-0002-0277-0186
Autonomous University of San Luis Potosí · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because cancer is a multifactorial disease, it is difficult to identify the specific agents responsible for the disease's progression and development, but lifestyle and diet have been shown to play a significant role. Diverse natural compounds are demonstrating efficacy in the development of novel cancer therapies, including sulforaphane (1-isothiocyanate-4-(methylsulfinyl)butane), a compound found in broccoli and other cruciferous vegetables that promotes key biological processes such as apoptosis, cell cycle arrest, autophagy, and suppression of key signalling pathways such as the PI3K/AKT/mTOR pathway in breast cancer cells. However, one of the primary challenges with sulforaphane treatment is its low solubility in water and oral bioavailability. As a consequence, several investigations were conducted using this component complexed in nanoparticles, which resulted in superior outcomes when combined with chemotherapy drugs. In this study, we discuss the properties and benefits of sulforaphane in cancer therapy, as well as its ability to form complexes with nanomolecules and chemotherapeutic agents that synergize the antitumour response in breast cancer cells.

Indexed as

Anticarcinogenic AgentsBreast NeoplasmsButanesFemaleHumansIsothiocyanatesNanomedicinePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktThiocyanatesTOR Serine-Threonine KinasesWaterAnticarcinogenic AgentsButanesIsothiocyanatesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktThiocyanatesTOR Serine-Threonine KinasesWaterbreast cancernanomoleculesulforaphane

Identifiers

PMID36295538
PMCPMC9610969
OpenAlexW4303856642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.